Similar companies
Income Statement (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Revenue | 9.1M | 31% |
| Gross Profit | -21M | 13.9% |
| Cost of Revenue | 31M | 4.1% |
| Operating expense | 154M | 5.4% |
| Net Income | -136M | 7.7% |
Balance Sheet (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Total Assets | 1.17B | 1.5% |
| Total Liabilities | 211M | 4.4% |
| Total Equity | 963M | 0.9% |
| Shares Outstanding | 102M | 3.6% |
Cash Flow (USD)
| Q3 '24 | QoQ | |
|---|---|---|
| Cash from operations | -85M | 45.8% |
| Cash from investing | -7.7M | 68.1% |
| Cash from financing | 82M | 99.3% |
EPS
Financial Highlights for Intellia Therapeutics in Q3 '24
Intellia Therapeutics reported a revenue of 9.1M, which is a 31% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at -21M, marking a 13.9% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 31M, a -4.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 154M, showing a 5.4% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -136M, showing a 7.7% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for Intellia Therapeutics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies.
